2 Red Flags for Bluebird Bio Stock
The biotech's struggles may continue.
Source: yahoo.com
Hematologic Malignancy News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Hematologic Malignancy. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Hematologic Malignancy Today - Breaking & Trending Today
Should You Invest in Bluebird Bio Right Now?
After two December share price crashes, there's no evident cure for Bluebird Bio's ills.
Source: yahoo.com
Lisocabtagene maraleucel may induce remission in relapsed chronic lymphocytic leukemia (CLL)
1. Complete response or remission was reported in 18% of patients who received a single liso-cel infusion. 2. Nearly 10% of fatalities were thought to be due to liso-cel related complications. Evidence Rating Level: 1 (Excellent) Study Rundown: There exist limited options for patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic
Source: 2minutemedicine.com
The Menarini Group Announces ELZONRIS® (Tagraxofusp) Designated as an Orphan Drug for BPDCN by Japanese Ministry of Health, Labor and Welfare
The Menarini Group ("Menarini"), a leading international pharmaceutical and diagnostics company, and Stemline Therapeutics, Inc. ("Stemline"), a wholly-owned subsidiary of the Menarini Group, today announced that Nippon Shinyaku Co., Ltd. (Nippon Shinyaku), Stemline's development partner in Japan, received Orphan Drug Designation for tagraxofusp, from the Japanese Ministry of Health, Labor and Welfare (MHLW) for the expected indication of blastic plasmacytoid dendritic cell neoplasm (BPDCN).
Source: yahoo.com
Dr Mead on the Use of Zanubrutinib vs Ibrutinib in MCL
Monica D. Mead, MD, discusses the efficacy and safety differences between the second-generation BTK inhibitor zanubrutinib and the first-generation BTK inhibitor ibrutinib in patients with mantle cell lymphoma.
Source: onclive.com